Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations.

Area of Science:

• Molecular Biology
• Epigenetics
• Cancer Research

Background:

• DNA methylation, regulated by DNA methyltransferases (DNMTs), is crucial for development.
• Mutations in DNMT3A, particularly at Arg882 (R882), are linked to acute myeloid leukemia (AML) pathogenesis.
• The molecular mechanisms behind DNMT3A R882 mutation-induced dysfunction are not fully understood.

Purpose of the Study:

• To elucidate the structural and mechanistic basis of DNMT3A R882 mutations.
• To investigate how these mutations affect DNMT3A oligomerization and DNA methylation.
• To explore therapeutic strategies targeting DNMT3A dysfunction in AML.

Main Methods:

• X-ray crystallography of the DNMT3A methyltransferase domain.
• Biochemical assays to assess polymerization and enzyme activity.
• Cellular and genomic DNA methylation analyses.

Main Results:

• Crystal structures reveal DNMT3A oligomerization distinct from DNMT3B, with R882 mutations enhancing intermolecular contacts.
• DNMT3B-like mutations in DNMT3A inhibit R882-induced polymerization and increase substrate access.
• These changes abolish the dominant-negative effect of R882 mutations, correcting aberrant DNA hypomethylation in AML cells.

Conclusions:

• DNMT3A R882 mutations promote aberrant oligomerization and DNA hypomethylation in AML via a distinct mechanism from DNMT3B.
• Modulating DNMT3A oligomerization by mimicking DNMT3B function can reverse pathogenic effects.
• This study offers mechanistic insights and potential therapeutic avenues for AML treatment.